Comparative Pharmacology
Head-to-head clinical analysis: KOGLUCOID versus NAGLAZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOGLUCOID versus NAGLAZYME.
KOGLUCOID vs NAGLAZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOGLUCOID (velaglucerase alfa) is a recombinant form of human glucocerebrosidase, which catalyzes the hydrolysis of glucocerebroside to glucose and ceramide. It replaces the deficient enzyme in patients with Gaucher disease, reducing accumulation of glucocerebroside in macrophages.
NAGLAZYME (galsulfase) is a recombinant form of human N-acetylgalactosamine 4-sulfatase that replaces deficient endogenous enzyme in patients with mucopolysaccharidosis VI (MPS VI). It catalyzes the hydrolysis of N-acetylgalactosamine 4-sulfate groups from glycosaminoglycans (GAGs), reducing GAG accumulation in lysosomes.
60 U/kg intravenously over 4 hours every 2 weeks.
1 mg/kg intravenously once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 15-30 minutes (range 11-35 min) in plasma after IV infusion. Short half-life necessitates frequent dosing (every 2 weeks). This reflects rapid clearance via receptor-mediated uptake into macrophages.
Terminal elimination half-life: 6-9 minutes (0.1-0.15 hours); clinically, rapid clearance requires weekly intravenous administration to maintain therapeutic levels.
KOGLUCOID (velaglucerase alfa) is a recombinant human glucocerebrosidase used for Gaucher disease. It is a protein therapeutic; elimination occurs via catabolism (proteolysis) to small peptides and amino acids. No significant renal or biliary excretion of intact drug. <1% excreted unchanged in urine.
Renal: 87% of administered dose excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy